

: 616.1/4 - 06 - 085.322

- 1 . . . , . . . " : ,
- 2 . . . , . . . " "
- 1 . . . , . . . "
- 1 . . . , . . . " ,
- . . . , . . .
- 2 . . . , . . .

()

: - , , [31, 32].

1/3

"?

[4, 5].

[1, 7, 8, 15, 29].

8-10 - 70 40 , 5-7 - 2-4 60 () .

50-60

(, , , ,) ,

[3, 6, 8].

(comorbid oliseases, comorbidity), (multimorbidity) [12, 14, 16, 33].

[17, 19]:

• - (.) .

• ;

• ;

• ;

• ;

. Diehm (1996)

1.		
2.		
3.		
4.	” , ”	
5.		
6.		

- 4 8 -
 (.) 3 55, 64,5 82,3%
 [19].
4.
 1. () , -
 2. , -)
 3. , ,
 4. () , ,
 5. , (,)
 6. () , ,
 7. (, , - ,
 8.)
 [22, 27, 28].
5.
 [2],
1. , -
 10- [21]. AH1N1 2009-2010 , -
 , 20% -
 , 12% - [11]. , 14% - 60%
 , 16% - , 10% - , 20% -
 10% 19 80% ()
 [20, 22, 27, 28]. , (- ,) [1, 2, 23].
2. **7.**
 . 1 [21, 23, 35],
 ; 2-2,5 , 2,5-3,3
3. - 2,5-3 , -2,2-3
 ; (,)
4 2,2011

() (Index
 Coexisting Disease - ICED),
 [21, 23, 35].
 8. [19, 21, 35].
 [23, 31]. [6].
 9. [33, 35]. ()
 10. [21, 23, 27, 29, 33].
 11. [25, 30, 34]. ()
 2000
 1993
 300,
 2010 2000 - 2800, 2007 - 22000 [5]. 16800,
 [18], () [24, 25, 30, 34].
 - 3 ; - 1 , 50-59 - 1 - 2 , 60-79 ,
 - 2 , 70-79 - 3 , 80 - 4 , 2-
 77 ,
 : - 3 , - 2 ,
 - 3 , - 1 , - 1 . - 10
 3
 [19, 26],
 4 3- 65%, 6-8 55%,
 6 82%, 1, 23,). ()
 (Cumulative illness rating scale - CIRS) -

- (F)
- 3 4 ().
- 1.
 - 2.
 - 3.
 - 4.
1. // . . . 2009.- 12.- 69-71.
 2. / . . . // - , 2010.-300 . //
 3. , 2004, 9- 71-74.
 4. . . . // - : . - 2007. - 525 .
 5. / . . . " , 2010. - 60-61.
 6. " , 2002. - 352 .
 7. / . . . // - . - 2010.- 3.- C.96-105.
 8. / . . . // . - 2009. - 6.- 81-83.
 9. AHA/NKF. *Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease* // - *Circulation*-2006;114:1083-7.
 10. Aronow W.S. et al. *Prevalence of CAD, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary events in older persons with chronic renal insufficiency and with normal renal function* // - *Am. J. Card.* 2000;86:1142-1143.
 11. Australian Institute of Health and Welfare (AIHW): *Chronic diseases and associated risk factors in Australia.* - Canberra, ACT; 2006.
 12. Bayliss E.A. *Descriptions of Barriers to Self-Care by Persons with Comorbid Chronic Diseases.* / E.A. Bayliss, J.F. Steiner, D.H. Fernald et al // - *Ann Fam. Med.* -2003;1(1):15-21.
 13. Baumler S. *Heilpflanzen Praxis Heute.* - Urban u. Fischer, Munchen, 2007. - 989 S.
 14. Bont J. *Is co-morbidity taken into account in the antibiotic management of elderly patients with acute bronchitis and COPD exacerbations?* / E. Hak, C.E. Birkhoff et al. // - *Fam.Pract.* - 2007, Vol. 24(4), P. 317-322.
 15. Boyd C.M. *Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid Diseases: Implications for Pay for Performance.* / C.M. Boyd, J. Darer, C. Boulton et al. // - *JAMA.* -2005, Vol. 294(6). - P. 716-724.
 16. Braithwaite R.S. *A Framework for Tailoring Clinical Guidelines to Comorbidity at the Point of Care.* / R.S. Braithwaite, J. Concato, C.C. Chang et al. // - *Arch. Intern. Med.* -2007, Vol. 167(21). - P. 2361-2365.
 17. Caughey G.E., *Prevalence of comorbidity of chronic diseases in Australia.* / G.E. Caughey, A.I. Vitry, A.L. Gilbert, E.E. Roughton // - *BMC Public Health.* - 2008, Vol. 8. - P. 221.
 18. Charlson M.E. *A new method of classifying prognostic comorbidity in longitudinal studies: development and validation* / M.E. Charlson, P. Pompei, K.L. Ales, C.R. McKenzie // - *J. Chron. Dis.* - 1987, Vol. 40(5). - P. 373- 383.
 19. De Groot V. *How to measure comorbidity: a critical review of available methods.* / V. De Groot, H. Beckerman, G. Lankhorst et al. // - *J. Clin. Epidemiol.* - 2003, Vol. 56. - P. 221-229.
 20. Edmondstone W.M. *Chest pain and non-respiratory symptoms in acute asthma.* / W.M. Edmondstone // - *Postgrad. Med. J.* - 2000, Vol. 76(897). - P. 413-414.
 21. Gonzalez A. *Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?* / A. Gonzalez, H.M. Kremers, C.S. Crowson et al. // *Ann. Rheum. Dis.* - 2008, Vol. 67. - P. 64-69.
 22. Kiss D. *Bronchial asthma causing symptoms suggestive of angina pectoris* / D. Kiss, W. Veegh, D. Schragel et al. // - *Eur. Respir. J.* - 2003. Vol. 21(3). - P. 473-477.
 23. Kongkaew C. *Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies* / C. Kongkaew, P.R. Noyce, D.M. Ashcroft // - *Ann. Pharmacother.* - 2008, Vol. 42(7). - P. 1017-1025.
 24. Loew D. *EBM: Evidens-based (Phyto) Medicine Versus Experience-based (Phyto) Medicine* / D. Loew // - *Z. Phytother.* 2000, Vol. 21, 2 - P. 71-77.
 25. Loew D. *Wirksamkeit und Sicherheit praxiszele vanter Phytopharmaka* / D. Loew // - *Z. Phytother.* - 2005 - Vol. 26, 3 - P. 119-126.
 26. Marti S. *Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy* / S. Marti, X. Munoz, J. Rios et al. // - *Eur Respir. J.* - 2006, Vol. 27(4). - P. 689-696.

27 Sin D.D. Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Morbidity and Mortality/D.D. Sin, S.F.P. Man // Proc. Am. Thorac. Soc. - 2005. T. 2. - P. 8- 1.

28 Salpeter S.R. Meta-Analysis: Effect of Long-Acting {beta}- Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths.- Ann. Intern. Med. /S.R. Salpeter, N.S. Buckley, T.M. Ormiston et al. // - 2006, Vol. 144. - P. 904-912.

29 Van den Akker M. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. / Van den Akker M., F. Buntinx, J.F. Metsemakers et al. // - J Clin Epidemiol. - 1998, Vol. 51 (5). - P. 367-375.

30 Schulz V. Arzneimittelinteraktion: Relevanz für Phytopharmaka / V. Schulz // - Z. Phytother. - 2004 - Vol.25, 6 - P. 283-288.

31 Starfield B., Comorbidity: Implications for the Importance of Primary Care in 'Case' Management / B. Starfield, K.W. Lemke, T. Bernhardt et al. // - Ann. Fam. Med. - 2003, Vol.1(1). - P. 8-14.

32 Struijs J.N. Comorbidity in patients with diabetes mellitus: impact on medical health care utilization / J.N. Struijs, C.A. Baan, F.G. Schellevis et al. // - BMC Health Serv Res. - 2006, 6. - P. 84.

33 Wang P.S. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives / P.S. Wang, J. Avorn, M.A. Brookhart et al. // - Hypertension. - 2005, Vol.46(2). - P.273-279.

34 Wagner H. Neue Entwicklungen und Ergebnisse der phytomedizinischen Forschung. / H. Wagner // Z. Phytother. - 2002 - Vol.23, 4 - P. 164-168.

35 Van Weel C., Comorbidity and guidelines: conflicting interests. / Van Weel C., F.G. Schellevis // Lancet. - 2006, 367. - P. 550-551.

07.02.2011

: 616.1/4 - 06 - 085.322

**O.I. Voloshyn, T.P. Garnyk, L.O. Voloshyna, V.L. Vasyuk
THE APPLICATION OF HERBAL REMEDIES IN
THE CLINIC OF INTERNAL DISEASES AS ONE OF THE
IMPORTANT WAY OF THE SOLUTION OF COMORBIDITY
PROBLEMS**

(review of literature and original investigation)

Key words: comorbidity, diseases of internal organs, treatment, application of herbal remedies, perspectives

The problem of comorbidity in the clinic of internal medicine, the common nonspecific pathophysiological links lying in the basis of comorbidity, debatable questions of diagnostics, treatment and prognostic tendencies had been considered. The application of herbal remedies in contemporary standards of therapy is considered as one of the most important way of the improvement of treatment results in patients with comorbidity conditions. The necessity of further research of comorbidity diseases, making supplements in existing treatment standards of diseases of internal organs in type of multicomponent herbal remedies, professional training of physicians of general practice-family medicine in branch of phytotherapy are grounded.

612.275: 616.248: 615.015: 615.032

2
12
1
^

2

:

() [27,40,44].
(),
(),